Answers are grounded in this paper and cite their sources.
Despite improving survival rates, a significant number of children, adolescents and young adults (CAYA) with relapsed/refractory acute lymphoblastic leukemia (r/r ALL) still die from disease. This calls for new drugs combination to reinduce complete remissions (CR) and enable consolidation. B-cell lymphoma (BCL) family proteins have a key role in regulating the blast apoptotic response to chemotherapy-induced cell damage and the combination of the BCL-2 and BCL-XL/BCL-2 inhibitors (venetoclax [VEN] and navitoclax [NAV], respectively) with chemotherapy could revert the resistance observed in r/r ALL. We retrospectively collected data of NAV/VEN, combined with chemotherapy, in 30 CAYA with advanced, R/R, either B-ALL (n=17) or T-ALL (n=13), treated under compassionate use, in 5 European centers. NAV and VEN (median number of cycles 1, range 1-3) were administered over 28 days. The most common toxicity was hematologic: overall, 93% of the patients developed grade 3-4 neutropenia, 83% grade 3-4 anemia and 83% grade 3-4 thrombocytopenia. No fatal adverse event was recorded. The overall response rate (CR/CRi/PR) was 71% for the B-ALL (12/17 patients) and 50% (6/12) for the T-ALL cohort, allowing, respectively, 11 and 4 patients to receive further consolidation. Six B-ALL patients and 2 T-ALL patients are alive and maintain response, with a median follow-up of 25 (0,6 - 38) and 8 months (0.5-47), respectively. All patients who did not receive consolidation ultimately relapsed and died. Our experience underlines the strong potential of NAV/VEN plus conventional chemotherapy to reinduce complete remission in heavily pretreated and refractory CAYA with either B- or T-ALL.
No takes yet. Share an insight, caveat, or question.
Bufalo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: